SanBio Co (TSE:4592) EBIT per Share : 円-27.14 (TTM As of Jul. 2024)

View and export this data going back to 2015. Start your Free Trial

What is SanBio Co EBIT per Share?

SanBio Co's EBIT per Share for the three months ended in Jul. 2024 was 円-18.58. Its EBIT per Share for the trailing twelve months (TTM) ended in Jul. 2024 was 円-27.14.

During the past 3 years, the average EBIT per Share Growth Rate was 14.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for SanBio Co's EBIT per Share or its related term are showing as below:

TSE:4592' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -43.9 Med: -18.4 Max: 14.7
Current: 14.7

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of SanBio Co was 14.70% per year. The lowest was -43.90% per year. And the median was -18.40% per year.

TSE:4592's 3-Year EBIT Growth Rate is ranked better than
67.07% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs TSE:4592: 14.70

SanBio Co's EBIT for the three months ended in Jul. 2024 was 円-1,275.13 Mil.

SanBio Co EBIT per Share Historical Data

The historical data trend for SanBio Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co EBIT per Share Chart

SanBio Co Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

EBIT per Share

Get a 7-Day Free Trial

-99.96

-61.11

-87.20

-80.67

-38.76

SanBio Co Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
EBIT per Share	Get a 7-Day Free Trial															-15.24	1.82	-11.74	1.36	-18.58

SanBio Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

SanBio Co's EBIT per Share for the fiscal year that ended in Jan. 2024 is calculated as

	EBIT per Share		(A: Jan. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2531.587	/	65.323
=	-38.75

SanBio Co's EBIT per Share for the quarter that ended in Jul. 2024 is calculated as

	EBIT per Share		(Q: Jul. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1275.126	/	68.632
=	-18.58

EBIT per Share for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-27.14

SanBio Co (TSE:4592) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

SanBio Co EBIT per Share Related Terms

Thank you for viewing the detailed overview of SanBio Co's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

SanBio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044

Website

https://www.sanbio.com

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co Headlines

No Headlines